TY - JOUR
T1 - Human cardiac progenitor cells with regenerative potential can be isolated and characterized from 3D-electro-anatomic guided endomyocardial biopsies
AU - D'Amario, Domenico
AU - Leone, Antonio Maria
AU - Narducci, Maria Lucia
AU - Smaldone, Costantino
AU - Lecis, Dalgisio
AU - Inzani, Frediano
AU - Luciani, Marco
AU - Siracusano, Andrea
AU - La Neve, Federica
AU - Manchi, Melissa
AU - Pelargonio, Gemma
AU - Perna, Francesco
AU - Bruno, Piergiorgio
AU - Massetti, Massimo
AU - Pitocco, Dario
AU - Cappetta, Donato
AU - Esposito, Grazia
AU - Urbanek, Konrad
AU - De Angelis, Antonella
AU - Rossi, Francesco
AU - Piacentini, Roberto
AU - Angelini, Giulia
AU - Li Puma, Domenica Donatella
AU - Grassi, Claudio
AU - De Paolis, Elisa
AU - Capoluongo, Ettore Domenico
AU - Silvestri, Valentina
AU - Merlino, Biagio
AU - Marano, Riccardo
AU - Crea, Filippo
PY - 2017
Y1 - 2017
N2 - Aims: In the present study, we aimed to develop a percutaneous approach and a reproducible methodology for the isolation and expansion of Cardiac Progenitor Cells (CPCs) from EndoMyocardial Biopsies (EMB) in vivo. Moreover, in an animal model of non-ischemic heart failure (HF), we would like to test whether CPCs obtained by this methodology may engraft the myocardium and differentiate. Methods and results: EMB were obtained using a preformed sheath and a disposable bioptome, advanced via right femoral vein in 12 healthy mini pigs, to the right ventricle. EMB were enzymatically dissociated, cells were expanded and sorted for c-kit. We used 3D-Electro-Anatomic Mapping (3D-EAM) to obtain CPCs from 32 patients affected by non-ischemic cardiomyopathy. The in vivo regenerative potential of CPCs was tested in a rodent model of drug-induced non-ischemic cardiomyopathy. c-kit positive CPCs replicative capacity was assessed in 30 patients. Telomere length averaged 7.4±0.4kbp and telomerase activity was present in all preparations (1.7×105 copies). The in situ hybridization experiments showed that injected human CPCs may acquire a neonatal myocyte phenotype given the expression of the alpha-sarcomeric actin together with the presence of the Alu probe, suggesting a beneficial impact on LV performance. Conclusions: The success in obtaining CPCs characterized by high regenerative potential, in vitro and in vivo, from EMB indicates that harvesting without thoracotomy in patients affected by either ischemic or non-ischemic cardiomyopathy is feasible. These initial results may potentially expand the future application of CPCs to all patients affected by HF not undergoing surgical procedures.
AB - Aims: In the present study, we aimed to develop a percutaneous approach and a reproducible methodology for the isolation and expansion of Cardiac Progenitor Cells (CPCs) from EndoMyocardial Biopsies (EMB) in vivo. Moreover, in an animal model of non-ischemic heart failure (HF), we would like to test whether CPCs obtained by this methodology may engraft the myocardium and differentiate. Methods and results: EMB were obtained using a preformed sheath and a disposable bioptome, advanced via right femoral vein in 12 healthy mini pigs, to the right ventricle. EMB were enzymatically dissociated, cells were expanded and sorted for c-kit. We used 3D-Electro-Anatomic Mapping (3D-EAM) to obtain CPCs from 32 patients affected by non-ischemic cardiomyopathy. The in vivo regenerative potential of CPCs was tested in a rodent model of drug-induced non-ischemic cardiomyopathy. c-kit positive CPCs replicative capacity was assessed in 30 patients. Telomere length averaged 7.4±0.4kbp and telomerase activity was present in all preparations (1.7×105 copies). The in situ hybridization experiments showed that injected human CPCs may acquire a neonatal myocyte phenotype given the expression of the alpha-sarcomeric actin together with the presence of the Alu probe, suggesting a beneficial impact on LV performance. Conclusions: The success in obtaining CPCs characterized by high regenerative potential, in vitro and in vivo, from EMB indicates that harvesting without thoracotomy in patients affected by either ischemic or non-ischemic cardiomyopathy is feasible. These initial results may potentially expand the future application of CPCs to all patients affected by HF not undergoing surgical procedures.
KW - 3D-endomyocardial biopsies
KW - Cardiac progenitor/stem cells
KW - Cardiology and Cardiovascular Medicine
KW - Medicine (all)
KW - 3D-endomyocardial biopsies
KW - Cardiac progenitor/stem cells
KW - Cardiology and Cardiovascular Medicine
KW - Medicine (all)
UR - http://hdl.handle.net/10807/99260
UR - http://www.elsevier.com/locate/ijcard
U2 - 10.1016/j.ijcard.2017.02.106
DO - 10.1016/j.ijcard.2017.02.106
M3 - Article
SN - 0167-5273
SP - 330
EP - 343
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -